Navigation Links
Allen Kesselring, Ph.D. of EAG Life Sciences Featured in Special Report on Extractables and Leachables
Date:12/13/2012

Maryland Heights, Missouri (PRWEB) December 13, 2012

Allen Kesselring, Ph.D. , Scientific Director of EAG Life Sciences, recently participated in an industry roundtable for a special report on extractables and leachables (E&L) testing, published in the November 2012 issue of Pharmaceutical Technology and featured online at Pharmtech.com. Extractables and leachables continue to challenge the pharmaceutical industry, stirring increasing concerns from manufacturers. E&L investigations focus on potential organic and inorganic impurities released or migrated from packaging components into pharmaceutical products.

In the special report, “Examining the Growing Challenge of Extractables and Leachables”, Dr. Kesselring noted that these studies are most commonly associated with injectables, ophthalmics, and orally inhaled nasal drug products. The routes of drug delivery, length and quantity of exposures make for important considerations in extractable and leachable studies. Dr. Kesselring explains: “The quick and efficient transport of ingredients to the bloodstream, which makes these drug-delivery routes highly effective, also makes them susceptible to impurities arising from the packaging."

In the report, the roundtable experts discussed the changes and advancements in analytical testing for extractables and leachables. Dr. Kesselring explained that while analytical improvements have led to faster, more efficient assessments of E&Ls they have also allowed for increased regulatory expectations. He mentioned recent regulatory initiatives that require more specificity and lower limits of evaluation, such as the forthcoming USP General Chapters 232 and 233 involving elemental impurities and the “published for comment” glass delamination document of 1660.

More published information on extractables and leachables from Dr. Kesselring include:

About Allen Kesselring, Ph.D.
Allen Kesselring, Ph.D. serves as the Scientific Director of EAG Life Sciences. He maintains the scientific excellence, quality and timeliness of the contract research organization’s projects. In this role he serves as technical client liaison regarding GXP compliance. He may be reached for further questions at info.lifesciences@eaglabs.com or 800-659-6059.

About EAG Life Sciences
EAG Life Sciences is a contract laboratory with over 50 years of experience supporting pharmaceutical and medical device companies for their specialized research and development needs. Key services include analytical chemistry, method development and method validation, characterization, extractables and leachables studies, quality control testing and stability services. Clients receive high level of 1:1 technical interaction and responsiveness that is applied to both complex and routine studies. EAG Life Sciences is a division of Evans Analytical Group, global company providing technical services rooted in science. http://www.eaglabs.com.

Read the full story at http://www.prweb.com/releases/Allen/Kesselring/prweb10228986.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Marketing Xocolate International Corporation; Xocai, Announces Their 12-Week Weight Loss Challenge To Make Healthy Changes
2. Xocai Maryland
3. Xocai Massachusetts
4. Studies challenge standards to improve treatment outcomes for patients with clotting disorders
5. Research from ASCOS Quality Care Symposium shows advances and challenges in improving the quality of cancer care
6. Complications challenge rheumatoid arthritis patients after joint replacement surgery
7. Teen Smoking Has Fallen Across Most of U.S.: Report
8. Obese but happy gene challenges the common perception of link between depression and obesity
9. HIV and AIDS prevention--Progress and the challenges ahead
10. People in crowdsourcing challenge find defibrillators in Philadelphia
11. Weill Cornell receives $1.5 million in Grand Challenges Explorations grants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... March 24, 2017 , ... According to a new study by NCPA ... does not obey the rules Congress has directed the CBO to follow. The CBO ... reform would restore. Yet, it estimates a reduction in employer-based coverage due to the ...
(Date:3/24/2017)... ... , ... The iaedp Foundation, the premier provider of educational programs and training ... the full spectrum of disordered eating, announced today that the 2017 Symposium set a ... states and several countries converged on the Green Valley Resort in Las Vegas. ...
(Date:3/24/2017)... ... 24, 2017 , ... Shamanic healer and teacher Anahata Ananda ... Spiritual Awakening, proudly presents her Sacred Peru retreat with world famous shaman ... journey during the Summer Solstice will also be her final international retreat, Anahata ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... wanted to create a communications platform that positions them as the go-to thought ... ONS reinvented their online publication as an always-on, always-fresh news, views and advocacy ...
(Date:3/24/2017)... ... March 24, 2017 , ... On June 9, 2017, ... Claims Litigation seminar in Chicago, Illinois. She will present on: , Filing ... litigated under ERISA involve claims for long-term disability benefits. This session will ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... Mar 24, 2017 Research and Markets has ... Strategic Business Report" report to their offering. ... The report provides separate comprehensive analytics for the ... Europe , Asia-Pacific , Latin ... provided for the period 2015 through 2022. Also, a six-year historic analysis ...
(Date:3/24/2017)... , March 24, 2017  Eli Lilly ... announced plans to invest $850 million in its ... facilities across its U.S. enterprise, including research laboratories, ... investments are being driven by demand for Lilly ... potential medicines in development targeting cancer, pain, diabetes ...
(Date:3/24/2017)... 2017  Mirabilis Medical, a Seattle ... non-invasive surgery, announced today CE Mark authorization for ... uterine fibroids throughout the European Union.  The company ... the US Food and Drug Administration to begin ... the United States.  The Mirabilis System combines high-speed ...
Breaking Medicine Technology: